STOCK TITAN
  1. Home
  2. News
  3. BLUE

bluebird bio, Inc. - BLUE STOCK NEWS

Welcome to our dedicated page for bluebird bio news (Ticker: BLUE), a resource for investors and traders seeking the latest updates and insights on bluebird bio stock.

bluebird bio, Inc. (NASDAQ: BLUE) is a pioneering biotechnology company dedicated to researching, developing, and commercializing gene therapies aimed at treating severe genetic diseases. With a focus on transformative gene therapies, bluebird bio utilizes its proprietary lentiviral vector (LVV) gene addition platform to target a wide range of serious conditions. The company's mission is to develop potentially curative treatments by leveraging its integrated product platforms, which include gene therapy, cancer immunotherapy, and gene editing.

bluebird bio's operations are centered on a single segment dedicated to gene therapy innovation. Recent achievements highlight the company's commitment to advancing healthcare solutions. For instance, bluebird bio has formed strategic partnerships and collaborations aimed at accelerating the development of its gene therapies. These alliances provide critical support in bringing groundbreaking treatments to market.

Current projects at bluebird bio include clinical trials and research focused on severe genetic diseases. The company is exploring potential cures for conditions such as sickle cell disease, beta-thalassemia, and cerebral adrenoleukodystrophy. Financially, bluebird bio has demonstrated robust growth and resilience, underpinned by strategic investments and a strong pipeline of products poised for commercialization.

The company's products are designed to address unmet medical needs, offering hope to patients who suffer from debilitating genetic disorders. bluebird bio's dedication extends beyond product development to include patient advocacy and health equity initiatives, ensuring broader access to innovative therapies.

In a recent notable event, Dr. Charlotte Jones-Burton was appointed to bluebird bio's board of directors, bringing a wealth of experience in clinical development and health equity advocacy. This addition signifies the company's ongoing commitment to enhancing its leadership team with experts who can drive strategic growth and innovation.

News

bluebird bio, Inc. Announces Pricing of $125 Million Public Offering of Common Stock

Rhea-AI Summary
bluebird bio, Inc. (Nasdaq: BLUE) announced the pricing of its underwritten public offering of 83,333,333 shares of its common stock at a public offering price of $1.50 per share, with expected gross proceeds of $125 million. The company plans to use the net proceeds to support commercialization and manufacturing for its approved gene therapies and for working capital and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-45.68%
Tags
offering
-
News

bluebird bio, Inc. Announces Proposed Public Offering of Common Stock

Rhea-AI Summary
bluebird bio, Inc. (Nasdaq: BLUE) has announced a public offering of $150,000,000 of its common stock, with an option for underwriters to purchase an additional $22,500,000. The offering will support commercialization and manufacturing of its three approved gene therapies, ZYNTEGLO, SKYSONA, and LYFGENIA, as well as fund working capital and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20.33%
Tags
offering
-
News

Long-Term Data Presented at ASH Support beti-cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels

Rhea-AI Summary
bluebird bio inc. (NASDAQ: BLUE) presented updated data at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition, showing sustained transfusion independence and improvements in iron management in patients with transfusion-dependent beta-thalassemia treated with beti-cel. The data demonstrated durable transfusion independence and a continued positive safety profile in patients through up to nine years of follow-up, reflecting beti-cel's potential as a curative therapy. A total of 63 patients across four clinical studies received beti-cel, with 90.2% of patients in the Phase 3 studies achieving transfusion independence. The safety results following beti-cel treatment largely reflected known side effects, with 19% of patients experiencing beti-cel-related adverse events. Iron management outcomes showed that 69% of patients were able to stop chelation therapy, demonstrating reduced iron management burden in those patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News

Long-term Follow-up Data From bluebird’s Gene Therapy Program in Sickle Cell Disease Support Durable, Potentially Curative Benefits Through Stable Production of Anti-Sickling Adult Hemoglobin and Resolution of Vaso-Occlusive Events

Rhea-AI Summary
bluebird bio, Inc. (NASDAQ: BLUE) announced new and updated efficacy, safety, and health-related quality of life data from the Phase 1/2 HGB-206 Group C and Phase 3 HGB-210 studies of lovotibeglogene autotemcel (lovo-cel) gene therapy for sickle cell disease. The data presented at ASH show that lovo-cel has the potential to address the underlying cause of sickle cell disease and provide robust clinical benefits for patients, with 94% complete resolution of sVOEs and 88% complete resolution of VOEs achieved in evaluable patients. The therapy has shown a durable impact on the underlying cause of sickle cell disease, with reductions in VOE frequency and severity, and significant improvements in hemolysis markers and health-related quality of life measures.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

bluebird bio Details Plans for the Commercial Launch of LYFGENIA™ Gene Therapy for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events

Rhea-AI Summary
bluebird bio, Inc. (NASDAQ: BLUE) announced the U.S. commercial infrastructure for LYFGENIA, an FDA-approved gene therapy for sickle cell disease. LYFGENIA launch includes outcomes-based contract offerings for payers and a personalized patient support program. The wholesale acquisition cost of LYFGENIA is set at $3.1M. The therapy aims to deliver robust and sustained clinical benefits, reducing or eliminating vaso-occlusive events, and enhancing patients' healthcare utilization, future earnings, and life opportunities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-40.54%
Tags
none
-
News

bluebird bio Announces FDA Approval of LYFGENIA™ (lovotibeglogene autotemcel) for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events

Rhea-AI Summary
bluebird bio, Inc. (Nasdaq: BLUE) has received FDA approval for LYFGENIA™ (lovotibeglogene autotemcel), also known as lovo-cel, for the treatment of sickle cell disease in patients ages 12 and older who have a history of vaso-occlusive events (VOEs). LYFGENIA is a one-time gene therapy that has the potential to resolve vaso-occlusive events and is custom-designed to treat the underlying cause of sickle cell disease. The approval marks bluebird’s third ex vivo gene therapy approved by the FDA for a rare genetic disease and second FDA approval for an inherited hemoglobin disorder, cementing their position as a gene therapy leader.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-40.54%
Tags
fda approval
News

Engine Capital Sends Letter to 2seventy’s Board of Directors Outlining Steps to Maximize Shareholder Value

Rhea-AI Summary
Engine Capital LP, which owns approximately 3% of 2seventy bio, Inc.’s (Nasdaq: TSVT) outstanding shares, believes that the company could be conservatively worth ~$9 per share if it exclusively focuses on its most-valuable asset Abecma, reduces corporate overhead and makes improvements to the composition of the management team and board. The company is currently trading at a market capitalization of just $100 million, despite having a cash balance of $284 million and a 50% profit interest in Abecma that is likely worth at least a few hundred million dollars.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.55%
Tags
management
-
News

bluebird bio Reports Third Quarter 2023 Financial Results and Highlights Operational Progress

Rhea-AI Summary
bluebird bio, Inc. (NASDAQ: BLUE) reported continued strong commercial launches for ZYNTEGLO® and SKYSONA®, with 22 patient starts across both programs to date. The company ended the quarter with $227M in cash, cash equivalents, marketable securities, and restricted cash. They also entered into an advance agreement to sell a priority review voucher, if granted, for $103 million, potentially strengthening their cash position. Management will host a conference call at 8:00AM ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.27%
Tags
earnings
-
News

bluebird bio to Present New and Updated Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition

Rhea-AI Summary
bluebird bio, Inc. will present new long-term efficacy, safety, and health-related quality of life data from its gene therapy programs for sickle cell disease and beta-thalassemia at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition. The data demonstrate sustained improvements in patient outcomes and the maturity of the gene therapies. The company also announced that the FDA accepted the lovo-cel Biologics Licensing Application for Priority Review.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.74%
Tags
conferences
News

bluebird bio Enters into Advance Agreement to Sell Priority Review Voucher, if Granted, for $103 Million

Rhea-AI Summary
bluebird bio has entered into an agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV) in connection with the potential approval of lovo-cel for sickle cell disease. The Company will receive $103 million upon closing of the sale, contingent upon FDA approval of the biologics license application (BLA) for lovo-cel and granting of the PRV. The BLA has a goal date of December 20, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.3%
Tags
none

FAQ

What is the current stock price of bluebird bio (BLUE)?

The current stock price of bluebird bio (BLUE) is $8.5 as of December 20, 2024.

What is the market cap of bluebird bio (BLUE)?

The market cap of bluebird bio (BLUE) is approximately 89.7M.

What is bluebird bio, Inc.?

bluebird bio, Inc. is a biotechnology company focused on developing gene therapies for severe genetic diseases using its proprietary lentiviral vector platform.

What does bluebird bio specialize in?

bluebird bio specializes in gene therapy, cancer immunotherapy, and gene editing, aiming to provide curative treatments for serious genetic disorders.

What recent achievements has bluebird bio accomplished?

Recent achievements include strategic partnerships and the appointment of Dr. Charlotte Jones-Burton to the board, enhancing clinical development and health equity efforts.

What are some of bluebird bio's current projects?

Current projects include clinical trials for conditions such as sickle cell disease, beta-thalassemia, and cerebral adrenoleukodystrophy.

What is bluebird bio's financial condition?

bluebird bio has shown strong financial performance, supported by strategic investments and a robust pipeline of transformative gene therapy products.

What products does bluebird bio offer?

bluebird bio offers gene therapies designed to treat severe genetic diseases, addressing unmet medical needs and providing potential cures.

Who are bluebird bio's key partners?

bluebird bio partners with various organizations and experts to advance its gene therapy developments, enhancing its ability to bring innovative treatments to market.

How does bluebird bio ensure health equity?

bluebird bio focuses on patient advocacy and health equity initiatives to ensure broader access to its groundbreaking therapies.

Who is Dr. Charlotte Jones-Burton?

Dr. Charlotte Jones-Burton is a new board member of bluebird bio with extensive experience in clinical development and advancing health equity in the biopharmaceutical industry.

What is the significance of bluebird bio's gene therapy platform?

bluebird bio's lentiviral vector gene addition platform is significant for its potential to develop curative therapies for a wide range of severe genetic diseases.

Stock BLUE logo
bluebird bio, Inc.

Nasdaq:BLUE

BLUE Rankings

#4487 Ranked by Market Cap
N/A Ranked by Dividends

BLUE Stock Data

89.74M
9.65M
0.63%
43.69%
24.6%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
SOMERVILLE